Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777401 | 0.90 | LMNA (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL3237973 | 0.84 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL30976528 | 0.84 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL4703400 | 0.84 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL2441765 | 0.83 | CES2 (0.59) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL1279794 | 0.83 | ALDH1A1 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL10349262 | 0.83 | CES2 (0.59) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL13127271 | 0.79 | CES2 (0.55) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL27430241 | 0.79 | CES2 (0.55) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL28033327 | 0.79 | CES2 (0.55) | CES2CES1L3MBTL1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0412699-B1 | Nitrosothiol derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-04-27 | — | — | EP | claimed |
| US-5116861-A | Treatment of Hypertension and Angina Pectoris | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-05-26 | — | — | US | claimed |
| EP-0412699-A2 | Nitrosothiol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-02-13 | — | — | EP | claimed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | CES2 656/4885CES1 608/4885L3MBTL1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.